COAVE THERAPEUTICS
LIVE

Serial Number

97197299

Owner

Coave Therapeutics

Attorney

Pina Campagna

Filing Date

Dec 30, 2021

Add to watchlist:

No watchlists yet
View on USPTO

COAVE THERAPEUTICS Trademark

Serial Number: 97197299 • Registration: 6999420

COAVE THERAPEUTICS is a trademark filed by Coave Therapeutics on December 30, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Coave Therapeutics

63 bis Avenue Ledru-Rollin
Paris 75012 , FR

Entity Type: 99

Trademark Details

Filing Date

December 30, 2021

Registration Date

March 14, 2023

Published for Opposition

December 27, 2022

Goods & Services

Pharmaceutical preparations in the nature of viral systems, gene therapy systems, and nucleic acid delivery systems comprised of viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells used to deliver modified genetic material into other cells for medical purposes for the diagnosis, treatment or prevention of ophthalmological disorders, diseases of the central and peripheral nervous system, hereditary disorders, genetic disorders and disorders of monogenic origin; Pharmaceutical preparations and products in the nature of genetically modified cells for use in gene therapy for medical purposes; Pharmaceutical preparations, namely, vaccines, prophylactic pharmaceuticals in the nature of antigens, and other genetically modified pharmaceuticals cells or tissue for use in nucleic acid therapy, gene therapy and cell therapy; Drug delivery agents in the nature genetically modified compounds for medical, pharmaceutical or veterinary purposes; Biological tissue cultures for medical purposes; Chemical or biological reagents for medical, pharmaceutical or veterinary purposes, namely, for nucleic acid therapy, gene therapy and cell therapy; Biological preparations for medical, pharmaceutical or veterinary purposes, namely, for use in connection with medical and clinical gene therapy, nucleic acid therapy and cell therapy to diagnose, treat and prevent ophthalmological disorders, diseases of the central and peripheral nervous system, hereditary disorders, genetic disorders and disorders of monogenic origin

Product research and development in the fields of biotechnology, biology, biomedicine, pharmacy, medical sciences, gene therapy, chemistry and biochemistry; Biological, biomedical and pharmaceutical therapeutic research services; Research in the fields of pharmaceutical and biological therapeutic preparations, namely, gene therapy and nucleic acid delivery systems for use in clinical trials and post-marketing trials; Pharmaceutical research and development; Provision of scientific research information in the fields of pharmaceuticals, biomedicine, gene therapy, clinical trials and post-marketing trials; Biological research; Chemical analysis and research services; Providing medical and scientific research information in the field of clinical trials; conducting clinical trials for others; Medical research services

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 14, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 14, 2023 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 27, 2022 NPUB
PUBLISHED FOR OPPOSITION
Dec 27, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 7, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 22, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 21, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 21, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 21, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 4, 2022 GNRN
NON-FINAL ACTION E-MAILED
Oct 4, 2022 GNRT
NON-FINAL ACTION WRITTEN
Oct 4, 2022 CNRT
ASSIGNED TO EXAMINER
Oct 4, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 5, 2022 NWOS
NEW APPLICATION ENTERED
Jan 3, 2022 NWAP